ES2323456T3 - Productos genicos diferencialmente expresados en celulas de pecho cancerosas y sus metodos de uso. - Google Patents

Productos genicos diferencialmente expresados en celulas de pecho cancerosas y sus metodos de uso. Download PDF

Info

Publication number
ES2323456T3
ES2323456T3 ES03729383T ES03729383T ES2323456T3 ES 2323456 T3 ES2323456 T3 ES 2323456T3 ES 03729383 T ES03729383 T ES 03729383T ES 03729383 T ES03729383 T ES 03729383T ES 2323456 T3 ES2323456 T3 ES 2323456T3
Authority
ES
Spain
Prior art keywords
cell
baselineskip
gene
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03729383T
Other languages
English (en)
Spanish (es)
Inventor
Rhonda Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of ES2323456T3 publication Critical patent/ES2323456T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES03729383T 2002-01-08 2003-01-08 Productos genicos diferencialmente expresados en celulas de pecho cancerosas y sus metodos de uso. Expired - Lifetime ES2323456T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34563702P 2002-01-08 2002-01-08
US345637P 2002-01-08

Publications (1)

Publication Number Publication Date
ES2323456T3 true ES2323456T3 (es) 2009-07-16

Family

ID=23355844

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03729383T Expired - Lifetime ES2323456T3 (es) 2002-01-08 2003-01-08 Productos genicos diferencialmente expresados en celulas de pecho cancerosas y sus metodos de uso.

Country Status (11)

Country Link
US (1) US20060141455A1 (https=)
EP (2) EP1472375B1 (https=)
JP (2) JP4376629B2 (https=)
AT (1) ATE427363T1 (https=)
AU (1) AU2003235791A1 (https=)
CA (1) CA2472282A1 (https=)
DE (1) DE60326931D1 (https=)
ES (1) ES2323456T3 (https=)
PT (1) PT1472375E (https=)
SG (1) SG148035A1 (https=)
WO (1) WO2003057926A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2004016225A2 (en) * 2002-08-19 2004-02-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2005233564A1 (en) * 2004-04-06 2005-10-27 The Regents Of The University Of California Orphan receptor tyrosine kinase as a target in breast cancer
WO2006017559A1 (en) * 2004-08-02 2006-02-16 University Of Iowa Research Foundation Methods of inhibiting manganese-containing superoxide dismutase 2 (mnsod)
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
US7694048B2 (en) * 2005-05-06 2010-04-06 Fotonation Vision Limited Remote control apparatus for printer appliances
AT502722B8 (de) * 2005-10-31 2009-08-15 Bmt Medizinische Forschung Und Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren
US20080113349A1 (en) * 2006-11-03 2008-05-15 Pranvera Ikonomi Method for detecting the presence of mammalian organisms using specific cytochrome c oxidase I (COI) and/or cytochrome b subsequences by a PCR based assay

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5993829A (en) * 1987-04-23 1999-11-30 Bystryn; Jean-Claude Anti-cancer vaccine
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP1690934A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5252296A (en) 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
EP0541693B1 (en) 1990-07-27 1998-12-09 Chiron Corporation Large comb-type branched polynucleotides
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
CA2098849C (en) 1990-12-20 2007-07-10 Dana-Farber Cancer Institute Control of gene expression by ionizing radiation
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2685346B1 (fr) * 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
WO1993014778A1 (en) 1992-01-23 1993-08-05 Vical, Inc. Ex vivo gene transfer
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ES2328424T3 (es) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. Vectores de alfavirus recombinantes.
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
US5571639A (en) * 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5985660A (en) * 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6974666B1 (en) 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5654173A (en) * 1996-08-23 1997-08-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
EP0937159A4 (en) 1996-02-08 2004-10-20 Affymetrix Inc SPECIATION OF MICROORGANISMS FROM MICROPLATES AND CHARACTERIZATION OF THE PHENOTYPES THEREOF
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
US6197543B1 (en) * 1997-10-28 2001-03-06 Incyte Pharmaceuticals, Inc. Human vesicle membrane protein-like proteins
JP2002522394A (ja) 1998-08-07 2002-07-23 ザ ジュネラル ホスピタル コーポレーション 中枢神経系虚血または外傷の上皮増殖因子様ポリペプチドによる治療
US6844325B2 (en) * 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
JP2002533402A (ja) 1998-12-31 2002-10-08 カイロン コーポレイション 癌を処置するためおよび樹状細胞の走化性を媒介するための方法
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
KR20030029847A (ko) 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Also Published As

Publication number Publication date
EP1472375B1 (en) 2009-04-01
DE60326931D1 (de) 2009-05-14
JP4376629B2 (ja) 2009-12-02
EP2075346A3 (en) 2009-11-11
ATE427363T1 (de) 2009-04-15
EP2075346A2 (en) 2009-07-01
AU2003235791A1 (en) 2003-07-24
US20060141455A1 (en) 2006-06-29
SG148035A1 (en) 2008-12-31
CA2472282A1 (en) 2003-07-17
PT1472375E (pt) 2009-05-19
JP2009142282A (ja) 2009-07-02
HK1066032A1 (en) 2005-03-11
EP1472375A1 (en) 2004-11-03
EP1472375A4 (en) 2006-03-15
JP2005525097A (ja) 2005-08-25
WO2003057926A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
WO2005000087A2 (en) Gene products differentially expressed in cancerous colon cells and their methods of use ii
CA2392398A1 (en) Nucleic acids, proteins, and antibodies
EP1165588A1 (en) Human breast and ovarian cancer associated gene sequences and polypeptides
JP2009142282A (ja) 癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
JP2001503980A (ja) 乳房の疾患の検出に有用な試薬および方法
TW200413539A (en) Genes and polypeptides relating to prostate cancers
US20030235533A1 (en) Prostate specific genes and the use thereof in design or therapeutics
US8216792B2 (en) Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
AU757478B2 (en) Compositions and methods for the identification of lung tumor cells
US20070128593A1 (en) Sga-1m, a cancer associated antigen, and uses thereof
WO1997028193A9 (en) Compositions and methods useful in the detection and/or treatment of cancerous conditions
WO1997028193A1 (en) Compositions and methods useful in the detection and/or treatment of cancerous conditions
JP2001522249A (ja) 尿路の疾患の検出に有用な試薬および方法
WO2002016939A2 (en) Methods of diagnosis of cancer and screening for cancer modulators
EP0960337B1 (en) Cathepsin K and breast cancer
HK1066032B (en) Gene products differentially expressed in cancerous breast cells and their methods of use
WO2004039943A2 (en) Human genes and gene expression products isolated from human prostate
US20070106065A1 (en) TAT- 001 and methods of assessing and treating cancer
ES2339322T3 (es) Procedimiento para la determinacion de ctp11 y para la determinacion del potencial metastasico de una muestra de tumor.
US20030087245A1 (en) Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer
US20050176930A1 (en) Marker molecules associated with lung tumors
US20100183630A1 (en) Tat-005 and Methods of Assessing and Treating Cancer
WO2006133145A2 (en) Tat-007 and methods of assessing and treating cancer
WO2006116541A2 (en) Tat-002 and methods of assessing and treating cancer
JPWO2001009317A1 (ja) 胃癌関連遺伝子